Results 181 to 190 of about 53,176 (324)

Positive Predictive Values of Familial Hypercholesterolemia Diagnoses in the Danish National Patient Registry and the Danish Familial Hypercholesterolemia Registry - A Validation Study. [PDF]

Clin Epidemiol
Knold J, Bork C, Snoer M, Heitmann M, Bang LE, Kanstrup H, Hansen KL, Hedegaard BS, Thomsen KK, Lauridsen BK, Bovin A, Lundquist AA, Al Tamimi HKS, Brorholt-Petersen JU, Christensen TE, Bertelsen MLN, Gohr T, Ellermann A, Hansen CP, Weis A, Nielsen PR, Schmidt EB, Bundgaard H, Henriksen FL, Danish Familial Hypercholesterolemia Study Group.   +24 more
europepmc   +1 more source

Co‐pathologies and biological processes beyond amyloid‐beta and tau in people with Alzheimer's disease: Evidence from clinical cohort studies

Journal of Internal Medicine, Volume 299, Issue 6, Page 694-710, June 2026.
Abstract Alzheimer's disease (AD) is neuropathologically defined by amyloid‐beta (Aβ) plaques and tau neurofibrillary tangles. However, co‐pathologies and other pathobiological processes are involved in the pathogenesis of AD, contributing to neurodegeneration and clinical symptoms.
Daniel Ferreira, Tomasz Chmiela, Maria Eriksdotter, Clifford R. Jack Jr., Grégoria Kalpouzos, Anna Marseglia, Patrizia Mecocci, Agneta Nordberg, Dorota Religa, Eric Westman   +9 more
wiley   +1 more source

No increased all-cause mortality in patients with genetically verified familial hypercholesterolemia (FH)– An overlooked success story? [PDF]

Karianne Svendsen, Kirsten B. Holven, Martin P. Bogsrud, Torbjørn Wisløff, Ivar S. Kristiansen, Jannicke Igland, Kjetil Retterstøl   +6 more
openalex   +1 more source

Identification of Alzheimer's disease subtypes and biomarkers from human multi‐omics data using subspace merging algorithm

Alzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) is a heterogeneous disease with diverse disease progression trajectories and brain pathology. Identifying AD subtypes is essential for understanding AD etiology, heterogeneity, and developing precise treatment. METHODS We applied a subspace‐merging algorithm to integrate multi‐omics data from brain tissues
Ziyan Song, Xiaoqing Huang, Asha Jacob Jannu, Travis S. Johnson, Jie Zhang, Kun Huang   +5 more
wiley   +1 more source

Aortic Stenosis in Homozygous Familial Hypercholesterolemia: The Canadian HoFH Registry. [PDF]

JACC Adv
Erzingatzian A, Al-Baldawi Z, Ruel I, Brown L, Sherman MH, Laflamme N, Bergeron J, Couture P, Paquette M, Baass A, Brisson D, Larouche M, Gaudet D, Cermakova L, Wan D, Brunham LR, Francis GA, Mancini GBJ, Kennedy BA, Hegele RA, Lewis GF, McCrindle BW, Ransom T, McPherson R, Piazza N, de Varennes B, Genest J, Iatan I.   +27 more
europepmc   +1 more source

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1309-1325, May 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

APOE genotype and the effect of statins on lipid outcomes: A meta‐analysis

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1268-1286, May 2026.
Aim APOE genotype may affect statin therapy response. We conducted a meta‐analysis to update and quantify this association across various outcomes. Methods We searched seven databases (MEDLINE, Scopus, Web of Science, the Cochrane Library, APA PsycINFO, CINAHL Plus and ClinicalTrials.gov) on 9 May 2024.
Innocent G. Asiimwe, Tsegay Gebru, Andrea L. Jorgensen, Munir Pirmohamed, on behalf of the Multimorbidity Mechanism and Therapeutics Research Collaborative   +4 more
wiley   +1 more source

Genetic Testing for Children with Familial Hypercholesterolemia. [PDF]

J Atheroscler Thromb
Nagahara K, Tada H, Dobashi K.
europepmc   +1 more source

Fruquintinib Plus TAS‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC.
Yi Wang, Jianfen Xu, Linchun Liang, Yunjie Chen, Leizheng Fei, Jing Hu, Jianjiong Li, Yi Lu, Feng Ren, Ke Chen, Yanping Shen, Qingsong Tao, Zhi Fang, Kaitai Liu, Hua Ye, Jing Zhang, Yunbao Xu, Haoxun Mao, Chen Zhang, Chuangzhou Rao   +19 more
wiley   +1 more source

Atherosclerosis in monogenic familial hypercholesterolemia versus polygenic hypercholesterolemia [PDF]

, 2016
Cooper, J, Futema, M, Gallivan, A, Harvey, D, Humphries, SE, Nair, D, Sharifi, M, Wah, LK   +7 more
core   +1 more source